Clostridium difficile coli%s. John K. Midturi January 2013
|
|
- Griselda Copeland
- 5 years ago
- Views:
Transcription
1 Clostridium difficile coli%s John K. Midturi January 2013
2 Objec%ves Describe pathogenesis of C. Diff coli%s Review methods of diagnosis of C. Diff coli%s Discuss treatment op%ons first episode refractory Review new pharmaceu%cals in the management of this disease Iden%fy complica%ons of C. Diff coli%s Review preventa%ve measures of infec%on Discuss pa%ent educa%on for eradica%on of C. Diff when discharged from the hospital
3 What are risk factors for Clostridium difficile? 1. Prolonged an%bio%c exposure 2. Advanced Age 3. Use of Proton Pump inhibitors 4. All of the above 0 of Countdown
4 Clostridium difficile coli%s 250,000 hospitalized cases annually in USA 1 2.5% mortality Annual cost: $433 $797 million Risk factors: Aging popula%on Increased healthcare exposure Increase in hospital procedures Environmental exposure
5 C. Diff clinical presenta%on Asymptoma%c Diarrhea Pseudomembranous coli%s Fulminant coli%s Recurrence: ~20% Persistence of intraluminal spores a^er treatment completed If two episodes of C. diff then recurrence >65% Lab: Leukocytosis, rising crea%nine
6 Pathogenesis An%bio%c Disrup%on of colonic flora Toxin producing C. difficile exposure Toxin release Mucosal injury & Inflamma%on
7 Pathogenesis Dependent on host and pathogen Host factors Toxin A an%body produc%on Asymptoma%c carriers demonstrate high levels of IgG an%body against toxin A compared to symptoma%c pa%ents Moun%ng a serum an%body response to toxin A during infec%on was associated with reduced recurrence rates Interleukin 8 levels Elevated IL 8 levels correlated with impaired humoral immune response to Clostridium difficile toxin A Frequency of IL 8 allele (associated with increase in IL8) with single nucleo%de polymorphism genotype AA significantly associated with development of CDI Intes%nal toxin receptors Absence of intes%nal receptors for C. difficile toxins in animal neonate models associated with asymptoma%c state. Coloniza%on with nontoxigenic strains Protec%ve factor against toxin producing strains
8 Other factors associated with pathogenesis An%bio%cs Disrupt normal colonic flora Clostridium difficile an%bio%c resistance to clindamycin(j strain) or quinolones Increased dura%on of an%bio%c therapy Advanced age Tenfold higher rates of infec%on if age>65yrs Diminished immune response Comorbid illnesses placing him at cumula%ve risk of infec%on (greater likelihood for hospitaliza%on or an%bio%c) Gastric acid suppression %mes higher risk of CDI amongst pa%ents exposed to PPI hkp:// Community associated infec%on Increased incidence of community acquired and hospital acquired infec%ons from Community acquired infec%ons less likely to have an%bio%c exposure, less PPI use, less frequency of cancer Retail food products and domes%c animals have been postulated is emerging sources
9 Who is at risk for recurrence? 2043 pa%ents with first posi%ve EIA Sept 2006 December (13%) died within 2 weeks 1678 (82%) followed up a^er 14 days 363 (22%) recurrence Predictors of CDI Recurrence CID 2012: 55:s77 s87
10 Who is at risk for recurrence? Inpa%ent (71%), median admission days 8 Older median age 77yrs 86% prior hospitaliza%on Emergency hospitaliza%on Higher CRP Higher neutrophil count h/o MRSA infec%on
11
12 When do they get recurrence?
13 C. Difficle diagnosis ELISA toxin A&B assay presence of toxin Inexpensive 24 hours Sn 60 95%, sp 99% CID 2007; 45: Tissue culture cytotoxicity for toxin B presence of organism, Gold standard (sn %, sp 99%) JID1984;149:781 Culture PCR Two step approach: Glutamate dehydrogenase an%gen (GDH) if posi%ve, followed by ELISA Toxin A/B
14 Alternative: Fidaxomicin 200mg BID x 10days Alternative: Fidaxomicin 200mg BID x 10days n engl j med 359;18 october 30, 2008
15 Treatment Ini%al Episode Mild Moderate Severe Metronidazole 500mg PO TIDx 10 14d Vancomycin 125mg PO QID x 10 14d n engl j med 359;18 october 30, 2008
16 Treatment First Recurrence Mild Moderate Severe Metronidazole 500mg PO TIDx 10 14d Vancomycin 125mg PO QID x 10 14d n engl j med 359;18 october 30, 2008
17 n engl j med 359;18 october 30, 2008
18 n engl j med 359;18 october 30, 2008
19 Treatment Second Recurrence Vancomycin Tapered & Pulsed Vancomycin 125mg QID x 14d BID x 7d QD x 7d QOD x 8d (4 doses) Every 3 days x 15d (5doses) n engl j med 359;18 october 30, 2008
20 Treatment Third Recurrence Vancomycin 125mg QID x 14d Rifaximin 400mg BID x 14d n engl j med 359;18 october 30, 2008
21 Other Op%ons IVIg 400mg/Kg every 3 weeks (total 2 3 doses) Fecal Transplant n engl j med 359;18 october 30, 2008
22 Treatment op%ons Discon%nue implicated an%microbial agent Ins%tute suppor%ve care Hydra%on and electrolyte replacement Avoid an% peristal%c Including narco%cs and loperamide Infec%on control Single room with bathroom Hand hygiene with soap and water Avoidance of rectal thermometers Terminal room cleaning with 1:10 household bleach
23 Complica%ons Inability to take oral medica%ons IV metronidazole 500 mg IV 4 %mes a day plus vancomycin 500 mg by reten%on enema or NG tube every 6 hours Delayed response in cri%cal illness Consider IVIG 400 mg/kg Surgical consulta%on for possible colectomy Prophylac%c metronidazole or oral vancomycin may increase rate of C. difficile carriage Not recommended
24 Treatment Agents
25 Vancomycin Has remained a highly effec%ve treatment agent Not absorbed Highly effec%ve for ini%al cure, recurrence rate of 20% No jus%fica%on for increased dose or extending the length of treatment Neither of these strategies has been tested high concentra%ons of vancomycin achieved by 125 mg dose
26 Vancomycin Pulse taper approach is prac%cal Decrease frequency to twice daily and once daily then every other day to every third day High cost Promo%ng overgrowth or coloniza%on of other pathogens such as enterococcus and Staphylococcus species Intracolonic vancomycin 500mg in 100ml NS q6 hours ileus
27 Metronidazole Uses first line treatment since 1994 Effec%ve for mild to moderate disease Increased failure rates and slower %me to symptom resolu%on Inferior to vancomycin for severe disease Clinical infec%ous diseases 2007; 45: th interscience conference on an%microbial agents and chemotherapy, 17 September Abstract L Severity based on white blood cell count and serum crea%nine level Infec%on control Hospital epidemiology 2010; 31: Highly absorbed Fecal concentra%ons are zero and asymptoma%c carriers Modest levels in pa%ents with diarrhea
28 Nitazoxanide Thiazolide compound that has an%parasi%c ac%vity Similar response rate to vancomycin and metronidazole clinical infec%ous diseases 2006; 43:421 7 Clinical infec%ous diseases 2009; 48: E Small size of these studies does not permit appropriate conclusion about non inferiority or superiority Ten day course of Nitazoxide a^er failing 14 days of metronidazole clinical cure rate 54% Relapse 20% Failure 26% Larger studies comparing the efficacy of Nitazoxanide with that of standard therapies are needed to help define its place in the management of CDI detested non inferiority to current available agents
29 rifaximin Nonabsorbable an%bio%c, somewhat flora sparing Subject to high level resistance cri%cal amino acid subs%tu%on in the beta subunit of the bacterial RNA polymerase Chaser 79% of pa%ents who had rifaxamin chaser had no recurrence Clinical infec%ous diseases 2007; 44:846 8 Anaerobe 2009; 15: Unresponsive to metronidazole 64% who were on rifaximin had stool cultures nega%ve at 56 day followup Therapeu%c advances of gastroenterology 2010; 3:221 5
30 Tigecycline Broad spectrum ac%vity Does not promote growth of C. difficle in human gut model No large compara%ve studies
31 Bacitracin Polypep%de an%bio%c similar to Vancomycin in controlling symptoms Inferior to Vancomycin in clearance from feces High level resistance noted Limited role in current management of CDI
32 Fusidic Acid CDI cure rates 83 93% Recurrence rate 28% High rates of resistance Not available in USA Limited role in current management of CDI
33 Teicoplanin Glycopep%de an%bio%c similar to Vancomycin Cure rates and recurrence rates similar Not available in USA
34 Anion binding resins Advantage Bowel flora is not altered, as occurs with vancomycin or metronidazole. More rapid recons%tu%on of the normal colonic flora. Disadvantage Bind vancomycin as well as toxins; thus, the resin must be taken at least two or three hours apart from the vancomycin. Coles%pol and cholestyramine are not effec%ve as primary therapy for CDI may be beneficial as adjunc%ve therapy for relapsing infec%on. Coles%pol (5 g every 12 hours) or cholestyramine (4 g three or four %mes daily) for one to two weeks, usually with vancomycin. Tolevamer is a C. difficile toxin binding resin developed specifically for CDI inferior to both vancomycin and metronidazole as primary therapy for CDI
35 Fidaxomicin Macrocylic an%bio%c bacteriocidal against Clostridium difficile (metronidazole and vancomycin her bacteriosta%c) More narrow an%microbial spectrum less disrup%on of normal colonic anaerobic microflora. Clinical cure rates similar to vancomycin, but less relapses Cost ~$3000/course
36
37
38
39 Other op%ons Nitazoxanide 500mg BID x 10 days Useful if intolerance to 1 st line Abdominal pain, nausea Rifaximin 200mg TID x 10days Useful as chaser Nausea, dizziness, fa%gue Tigecycline 100mg IV then 50mg IV BID IV op%on Nausea, vomi%ng Fecal Transplant 95% cure rates
40 Factors for severe disease Presence of 2 or more Age >60 Fever >100.9 Albumin <2.5mg/dL WBC >15,000 Pseudomembranous coli%s >10 BM/day WBC>20,000 Severe abdominal pain Crea%nine >1.5 %mes baseline
41
42 So how do we prevent transmission of Clostridium difficile? Contact precau%ons Gloves for all pa%ent contact Placement in single room with associated bathroom Pa%ent cohort in may be reasonable Wash hands with soap and water Environmental cleaning 1 10 dilu%on of household bleach Caus%c to environmental surfaces An%bio%c streamlining
43 How about Probio%cs? Microorganisms to counteract disturbances and intes%nal flora and thereby reduce risk of coloniza%on by pathogenic bacteria Low cost in low incidence of associated adverse events Akrac%ve choice for preven%on of CDAD
44 Ann Intern Med. 2012;157(12): From: Probiotics for the Prevention of Clostridium difficile Associated Diarrhea: A Systematic Review and Meta-analysis Randomize, controlled trials an adult and pediatric pa%ents treated with an%bio%cs comparing the effect of any dose of specific probio%c with placebo or no treatment
45 Ann Intern Med. 2012;157(12): From: Probiotics for the Prevention of Clostridium difficile Associated Diarrhea: A Systematic Review and Meta-analysis Figure Legend: Summary of evidence search and selection. AMED = Allied and Complementary Medicine Database; CD = Clostridium difficile; CDAD = Clostridium difficile associated diarrhea; CENTRAL = Cochrane Central Register of Controlled Trials; RCT = randomized, controlled trial. * Sources were BIOSIS Previews, Canadian Agency for Drugs and Technology in Health, Dissertation Abstracts, Google Scholar, British Society of Gastroenterology Annual General Meeting, McGill University Technology Assessment Unit, Inflammatory Bowel Disease/Functional Bowel Disease register, Copyright the Turning The Research American Into Practice College of database, Physicians. HighWire, clinical trial registries industry contact, and bibliographies. All rights reserved.
46 Ann Intern Med. 2012;157(12): From: Probiotics for the Prevention of Clostridium difficile Associated Diarrhea: A Systematic Review and Meta-analysis Copyright The American College of Physicians. All rights reserved.
47 Ann Intern Med. 2012;157(12): From: Probiotics for the Prevention of Clostridium difficile Associated Diarrhea: A Systematic Review and Meta-analysis Copyright The American College of Physicians. All rights reserved.
48 Ann Intern Med. 2012;157(12): From: Probiotics for the Prevention of Clostridium difficile Associated Diarrhea: A Systematic Review and Meta-analysis Copyright The American College of Physicians. All rights reserved.
Clostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationdeclara&ons Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD.
Clostridium difficile infec&on. Time to wake up and smell the..., um, nevermind. OK, next slide please. Bruce Dalton, BScPhm. PharmD. declara&ons No financial disclosures Personal acquaintance, co- worker,
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationBezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More information! MQ is a 44 year old woman that I first saw in Sept ! In MVA in Jan 2003 requiring spinal surgery
Case MQ is a 44 year old woman that I first saw in Sept 2006 UPDATE ON CLOSTRIDIUM DIFFICILE DISEASE Richard A. Jacobs, M.D.,PhD In MVA in Jan 2003 requiring spinal surgery Subsequently developed fecal
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationPatient presentation
Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationClostridium Difficile colitismore
Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More informationRespiratory Tract Infec1ons Long Term Care. Dr Karsten Hammond Infec1ous Diseases 28 March 2015
Respiratory Tract Infec1ons Long Term Care Dr Karsten Hammond Infec1ous Diseases 28 March 2015 Disclosures I have no financial rela1onships to disclose 82 yo Female In LTC for two years, total care from
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSMT19969: A Selective Therapy for C. difficile Infection
SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationClostridium difficile
Clostridium difficile Alex Aspinall MD, PhD, FRCPC Clinical Assistant Professor, University of Calgary Division of Gastroenterology and Hepatology, South Health Campus www.seacourses.com 1 Learning Points
More informationC. difficile Infection: How it all comes out
C. difficile Infection: How it all comes out Larry Danziger, Pharm.D. Professor of Pharmacy and Medicine College of Pharmacy University of Illinois at Chicago The speaker has no conflicts to disclose.
More informationClostridium difficile
Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence
More informationSponsored by Virox Technologies Inc. C. difficile 101 A brief review of guidelines and controversies
Controlling Clostridium difficile Outbreaks: Going Beyond the Guidelines Michael Gardam Infec
More informationTreatment of Clostridium Difficile Infec5on Gunter Schleicher Director, Wits DGMC ICU
Treatment of Clostridium Difficile Infec5on 2017 Gunter Schleicher Director, Wits DGMC ICU Community vs hospital acquired CDI Community acquired 1. Younger 2. Exposure to ancbioccs 3. Acid-suppression
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More information500,000 29,000. New 2015 Data. Lessa et al, N Eng J Med 2015: 34.2% of CDI cases were considered community-acquired
Cost-effective Treatment of Clostridium difficile Infection in the ICU Kevin W. Garey, PharmD, MS. Professor and Chair University of Houston College of Pharmacy New 2015 Data 500,000 29,000 Lessa et al,
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationDisclosure. Objectives. Assessment Questions. History. Clinical Case 2/27/2015. Clostridium difficile update and new therapies
Disclosure Clostridium difficile update and new therapies Corey Frederick, PharmD PGY-2 Pharmacy Resident, Infectious Diseases Jackson Memorial Hospital Miami, Florida I do not have a vested interest in
More informationResponders as percent of overall members in each category: Region: New England 50 (57% of 87 members) 46 (57% of 81 members) 21 (55% of 38 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Recurrent C. difficile Infections (CDI) Overall response rate: 621/1212 (51.2%) physicians responded from 09/26/12 to
More informationWayne Ghesquiere MD, FRCP(C) Infectious Diseases & Internal Medicine Victoria, BC
Wayne Ghesquiere MD, FRCP(C) Infectious Diseases & Internal Medicine Victoria, BC } Presentations for CHE and/or research from Abbott, Gilead, GSK, Merck, Pfizer, Roche, Sanofi-Pasteur. CFPC Disclosure
More informationFecal transplantation as a treatment option for recurrent Clostridium difficile infection
Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Josbert Keller Department of Gastroenterology Haga Teaching Hospital, The Hague Case: 81 yrs, CVA, recurrent UTI,
More informationClostridium difficile Essential information
Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationManagement of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,
More informationUnderstanding C. diff. atomalliance.org/cdifftraining
Understanding C. diff atomalliance.org/cdifftraining This booklet is a printed guide of the online educational resource atomalliance.org/cdifftraining Target Audience Understanding C. diff This educational
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More informationFecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond
Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have
More informationThe incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.
C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin
More informationClostridium difficile infections: Drug treatment re-evaluated
Clostridium difficile infections: Drug treatment re-evaluated Kimberly D. Leuthner, PharmD University Medical Center of Southern Nevada August 11, 2016 Random Fact: The human body has 10 13 human cells
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationC. difficile: The Changing Epidemiology Evaluations Clostridium difficile Thank You to our Sponsors
C. difficile: The Changing Epidemiology Ghinwa Dumyati, MD University of Rochester Monroe County Department of Public Health Thank You to our Sponsors Evaluations School of Public Health, University at
More informationLearning Goals. Clostridium difficile. Historical Context. Historical Context 6/27/2012
Learning Goals Clostridium difficile Justin L. Sewell, MD, MPH Assistant Clinical Professor of Medicine University of California San Francisco San Francisco General Hospital Understand the epidemiology,
More informationADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA
ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA Candace Marr, DO Catholic Health System University at Buffalo, NY Kevin Shiley, MD Catholic Health System Buffalo, NY FINANCIAL
More information6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations
CLOSTRIDIUM DIFFICILE PREVENTION Beth Goodall, RN, BSN Board Certified in Infection Prevention and Control DCH Health System Epidemiology Director Welcome! Teaming Up to Prevent Infections! CLOSTRIDIUM
More informationClostridium difficile Not Just a Hospital Problem Anymore. Objectives. The C. difficile Carrier State. Conflicts of Interest Disclosure
Conflicts of Interest Disclosure Daniel Leffler, MD, MS I disclose the following financial relationships with commercial entities that produce health carerelated products or services relevant to the content
More informationEPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)
EPIDEMIOLOGY AND PREVENTION OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics & Epidemiology Associate Chief Medical Offer, UNC Health Care Medical
More informationNursing Infectious Diseases Topics. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
Nursing Infectious Diseases Topics David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Clostridium difficile Free Access Via Web Source: Cohen SH,
More informationLong-Term Care Updates
Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationCLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates
CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections
More informationC. DIFFICILE UPDATE. Heather Bell, DO Infectious Diseases Physician
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Questions Testing recommendations Treatment recommendations
More informationL infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici
L infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici Roberto Luzzati SC Malattie Infettive, AOU Trieste Presidente :Prof. Enzo Raise Clinical presentation of infection
More informationHEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile
OBJECTIVES HEALTHCARE- ASSOCIATED INFECTIONS: A FOCUS ON Clostridium difficile Identify and describe the pathophysiology of C. diff. Identify and describe current therapies in treatment of C. diff Identify
More information7/30/2018 C. DIFFICILE UPDATE DISCLOSURE OUTLINE. Heather Bell, DO Infectious Diseases Physician. None to report
C. DIFFICILE UPDATE Heather Bell, DO Infectious Diseases Physician None to report DISCLOSURE Case review Review IDSA CDI guidelines discuss changes Testing recommendations Treatment recommendations Isolation
More informationClinical. Clostridium Difficile: Standard Operating Procedure. Document Control Summary. Contents
Clinical Clostridium Difficile: Standard Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationarguably the greatest risk to human health comes in the form of antibiotic-resistant bacteria. We live in a bacterial world where we will never be
arguably the greatest risk to human health comes in the form of antibiotic-resistant bacteria. We live in a bacterial world where we will never be able to stay ahead of the mutation curve. A test of our
More informationClinical Infectious Diseases IDSA GUIDELINE
Clinical Infectious Diseases IDSA GUIDELINE Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and
More informationC Difficile - The Ultimate Challenge: Controlling the Spread
C Difficile - The Ultimate Challenge: Controlling the Spread Linda R. Greene, RN, MPS, CIC Manager of Infection Prevention Highland Hospital Rochester, NY University of Rochester Medical Center linda_greene@urmc.rochester.edu
More informationPatient Safety Summit 2014
Patient Safety Summit 2014 The War on C Diff Mark Mellow, MD + C Diff The Organism Gram + bacillus Anaerobic Spore forming Intestinal flora (up to 35% hospitalized patients, 3% of healthy adults) Leading
More informationDuodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience
Duodenal infusion of donor feces for recurrent Clostridium difficile infection A French experience Benoit Guery Unité des Maladies Infectieuses CHRU - Faculté de Médecine Lille Conflicts of interest Conferences,
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationCorporate Medical Policy Fecal Microbiota Transplantation
Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description
More informationLe infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo
Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Istituto Nazionale per le Malattie Infettive «lazzaro Spallanzani», IRCCS-Roma The infectious cycle of transmission
More informationGUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS
GUIDELINE FOR THE MANAGEMENT OF ANTIBIOTIC- ASSOCIATED DIARRHOEA IN ADULTS Version 3.0 Date ratified May 2008 Review date May 2010 Ratified by NUH Antibiotic Guidelines Committee NUH Drugs and Therapeutics
More informationClinical Policy Bulletin: Fecal Bacteriotherapy
Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed
More informationClostridium difficile Infection (CDI) Guideline
Clostridium difficile Infection (CDI) Guideline Site Applicability All VCH PHC acute care and residential sites. Practice Level Physicians basic skill Pharmacists basic skill Nurses (RN, LPN, RPN) basic
More informationClostridium difficile
Clostridium difficile Sarah Doernberg, MD, MAS Assistant Professor, University of California, San Francisco Medical Director, Adult Antimicrobial Stewardship Disclosures: Consultant for Actelion, prior
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationClostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures?
Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures? Clostridium difficile Clostridium difficile - first described in 1935 when it was isolated
More informationClostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018
Clostridiodes Difficile Colitis: Update on Guidelines Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Outline Overview of CDI Diagnosis of C Difficile- updates Infection Prevention
More informationBacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management
Bacterial Therapy: Fecal Transplants, Probiotics and Non-Toxigenic Clostridium difficile for Clostridium difficile Infection (CDI) Management Dale N. Gerding, MD, MACP Professor of Medicine Loyola University
More informationClostridium difficile infections and fecal transplant
Objectives Clostridium difficile infections and fecal transplant Recognize patients at risk for C. difficile infection (CDI) Contrast diagnostic testing for CDI Describe treatment strategies for mild,
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationTreatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department
Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of
More informationFecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection
Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More information